A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Non-Small-Cell Lung Cancer
Both
Non-Small-Cell Lung Cancer
Trial Information
A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer
Inclusion Criteria:
- Diagnosis of metastatic non-small-cell lung cancer
- At least 18 years of age
- Have received 2 previous treatment regimens for metastatic non-small-cell lung cancer
Exclusion Criteria:
- Serious pre-existing medical conditions
- Previous cancer (except skin cancer, excluding melanoma)
- Have received 3 or more previous treatment regimens for metastatic non- small-cell
lung cancer
- Active treatment with Coumadin
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Time to progression
Outcome Time Frame:
baseline to measured progressive disease
Safety Issue:
No
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Investigator Role:
Study Director
Investigator Affiliation:
Eli Lilly and Company
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
9813
NCT ID:
NCT00363766
Start Date:
September 2006
Completion Date:
October 2008
Related Keywords:
- Non-Small-Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
